P42 Direct and Indirect Costs Associated with Major Depressive Disorder

Major depressive disorder (MDD) is a disabling mental health condition with significant economic burden. This study evaluated direct and indirect healthcare costs for patients MDD cost differences across severity levels. Adults (≥18 years) self-reported physician diagnosis of depression on the 2019 National Health Wellness Survey were stratified by disease using Patient Questionnaire (PHQ-9) scores: mild≤9, moderate=10-14, moderate-severe=15-19, severe≥20. The comparison population consisted participants representing general US without MDD, bipolar I disorder, or schizophrenia. Outcomes included estimated associated resource utilization (healthcare professional [HCP] visits, emergency room [ER] hospitalizations) work productivity loss. Cost outcomes (reported as annualized mean estimates) compared between cohorts, subgroups via multivariate analyses, adjusting key baseline differences. There 10,710 in cohort (severity: mild=5905, moderate=2206, moderate-severe=1565, severe=1034). In contrast to (N=52,687), adults had significantly higher 12-month total ($8814 vs $6072; P<.001), driven HCP visits ($3571 $1662; ER ($559 $366; hospitalizations ($4408 $3495; P=.007). Total greater versus ($5425 $3085; P<.001). Increased was increased (mild=$8220; moderate=$10,353; moderate-severe=$10,819; severe=$12,433; all P<.05 mild) (mild=$4490; moderate=$6537; moderate-severe=$7438; severe=$8797; P<.001 mild). Patients relative population. Compared mild costs. Results underscore need effective treatment regimens decrease severity.